Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The type 2 diabetes therapy market will steadily expand over our 2017-2027 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. However, these novel therapies predominantly represent later-to-market entrants from existing drug classes or novel combination therapies of existing compounds. Among the drug classes expected to undergo the most rapid growth are the sodium/glucose cotransporter 2 (SGLT 2) inhibitors—due to the cardiovascular (CV) benefit demonstrated by Jardiance—and the glucagon-like peptide 1 (GLP 1) receptor agonists—due to their efficacy, potential for weight loss, and the CV benefit associated with Victoza and Ozempic. However, these therapies will face major challenges in uptake, including reimbursement hurdles and an increasingly stringent regulatory environment.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Already a Client? Log in to access this report.
David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.
Amy Kaiser joined Decision Resources Group as an associate epidemiologist in 2017. Her focus is on the epidemiology of infectious diseases and niche and rare diseases. She holds an MS in Epidemiology from the University of Massachusetts, Amherst and a BA in International Relations from Mount Holyoke College. Prior to joining Decision Resources Group, she worked as a human health research associate at a environmental consulting firm where her epidemiology research focused on occupational and environmental exposures and associated outcomes.